Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...

CDK Global has successfully renewed its DMS agreement with Sonic Automotive, securing a key partnership following two ...

The news reinforces CDK's reputation in the DMS business and, presumably, will help the company land more extensions and new ...

In Hybrids amidst financial challenges. Read More CDK Global extends DMS contract with Sonic Automotive amid cyberattack ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

The contract extension with Sonic is a win for market leader CDK, which faced challenges over the summer after two ...

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

It hasn’t been the best of years for CDK Global, but it got some good news Monday. Sonic Automotive, one of the nation’s ...

A federal judge in Illinois has granted preliminary approval to a settlement in which CDK Global agrees to pay $100 million ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...